Enoxaparin sodium
- Generic Name
- Enoxaparin sodium
- Brand Names
- Lovenox, Inhixa
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 9005-49-6
- Unique Ingredient Identifier
- E47C0NF7LV
- Background
Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the incidence of venous thromboembolism in hosp...
- Indication
Enoxaparin is indicated for the prevention of ischemic complications in unstable angina and in non Q-wave myocardial infarction; it is indicated in conjunction with percutaneous intervention and/or other treatment for the management of acute ST elevation myocardial infarction.
...
- Associated Conditions
- Acute Coronary Syndrome (ACS), Acute Myocardial Infarction With ST Segment Elevation, Deep Vein Thrombosis, Ischemic complications caused by non-q wave myocardial infarction, Ischemic complications caused by unstable angina
- Associated Therapies
- Percutaneous Coronary Intervention (PCI)
Safety and Efficacy of Therapeutic Anticoagulation on Clinical Outcomes in Hospitalized Patients With COVID-19
- First Posted Date
- 2020-05-07
- Last Posted Date
- 2022-02-22
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT04377997
- Locations
- 🇺🇸
Abdurahman Khalil, Boston, Massachusetts, United States
Weight-Adjusted vs Fixed Low Doses of Low Molecular Weight Heparin For Venous Thromboembolism Prevention in COVID-19
- Conditions
- Interventions
- First Posted Date
- 2020-05-04
- Last Posted Date
- 2023-08-07
- Lead Sponsor
- Central Hospital, Nancy, France
- Target Recruit Count
- 1000
- Registration Number
- NCT04373707
- Locations
- 🇫🇷
Nancy Academic Hospital, Nancy, France
🇫🇷Dijon Academic Hospital, Dijon, France
🇫🇷Besançon Academic Hospital, Besançon, France
Comparison of Two Doses of Enoxaparin for Thromboprophylaxis in Hospitalized COVID-19 Patients
- First Posted Date
- 2020-04-29
- Last Posted Date
- 2021-06-08
- Lead Sponsor
- Niguarda Hospital
- Target Recruit Count
- 189
- Registration Number
- NCT04366960
- Locations
- 🇮🇹
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Milano, Italy
Preventing COVID-19 Complications With Low- and High-dose Anticoagulation
- First Posted Date
- 2020-04-15
- Last Posted Date
- 2021-09-14
- Lead Sponsor
- University Hospital, Geneva
- Target Recruit Count
- 160
- Registration Number
- NCT04345848
- Locations
- 🇨🇭
Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
🇨🇭Ospedale Regionale di Locarno, Locarno, Switzerland
🇨🇭Hôpital du Valais, Sion, Switzerland
Impact of Prophylactic Low-molecular Weight Heparin Dosing on Clotting Parameters Following Cesarean Delivery
- Conditions
- Interventions
- First Posted Date
- 2020-03-12
- Last Posted Date
- 2022-01-28
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 146
- Registration Number
- NCT04305756
- Locations
- 🇺🇸
University of Utah, Salt Lake City, Utah, United States
Comparison of Anticoagulation Prolongation vs. no Anticoagulation in STEMI Patients After Primary PCI
- First Posted Date
- 2018-09-10
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- Beijing Anzhen Hospital
- Target Recruit Count
- 2989
- Registration Number
- NCT03664180
- Locations
- 🇨🇳
Beijing Anzhen Hospital, Capital Medical University, Beijing, China
Prolonged Enoxaparin in Primary Percutaneous Coronary Intervention
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2022-11-15
- Target Recruit Count
- 100
- Registration Number
- NCT03568838
- Locations
- 🇬🇧
Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, South Yorkshire, United Kingdom
Edoxaban for the Treatment of Coagulopathy in Patients With Active Cancer and Acute Ischemic Stroke: a Pilot Study. (ENCHASE Study)
- Conditions
- Interventions
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2018-06-26
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 40
- Registration Number
- NCT03570281
- Locations
- 🇰🇷
Department of Neurology, Samsung Medical Center, Seoul, Korea, Republic of
Pilot Study of Rosuvastatin and Enoxaparin Thromboprophylaxis Following Ovarian Cancer Surgery (O-STAT Study)
- Conditions
- Interventions
- First Posted Date
- 2018-05-22
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 24
- Registration Number
- NCT03532139
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Prevention of Thromboembolic Events in Total Knee Replacement Patients
- First Posted Date
- 2018-01-08
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT03393481
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.